COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Linagliptin's Effect on CD34+ Stem Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02467478
Recruitment Status : Completed
First Posted : June 10, 2015
Last Update Posted : February 5, 2020
Boehringer Ingelheim
Information provided by (Responsible Party):
Sabyasachi Sen, George Washington University

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 2019
Actual Study Completion Date : December 2019